Global Somatostatin Analogue Drug Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Description

According to our (Global Info Research) latest study, the global Somatostatin Analogue Drug market size was valued at USD 6132.5 million in 2023 and is forecast to a readjusted size of USD 9534.6 million by 2030 with a CAGR of 6.5% during review period.

Somatostatin analogues are drugs that stop your body from making too many hormones. Some neuroendocrine tumours (NETs) make large amounts of hormones that cause a group of symptoms called carcinoid syndrome. Somatostatin analogues are a possible treatment for people with carcinoid syndrome.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Somatostatin Analogue Drug industry chain, the market status of Acromegaly (Octreotide, Lanreotide), Neuroendocrine Tumor (NET) (Octreotide, Lanreotide), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Somatostatin Analogue Drug.

Regionally, the report analyzes the Somatostatin Analogue Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Somatostatin Analogue Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Somatostatin Analogue Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Somatostatin Analogue Drug industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Octreotide, Lanreotide).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Somatostatin Analogue Drug market.

Regional Analysis: The report involves examining the Somatostatin Analogue Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Somatostatin Analogue Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Somatostatin Analogue Drug:
Company Analysis: Report covers individual Somatostatin Analogue Drug players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Somatostatin Analogue Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Acromegaly, Neuroendocrine Tumor (NET)).

Technology Analysis: Report covers specific technologies relevant to Somatostatin Analogue Drug. It assesses the current state, advancements, and potential future developments in Somatostatin Analogue Drug areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Somatostatin Analogue Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Somatostatin Analogue Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type
    Octreotide
    Lanreotide
    Pasireotide

Market segment by Application
    Acromegaly
    Neuroendocrine Tumor (NET)
    Others

Market segment by players, this report covers
    Camurus AB
    Chiasma
    Ipsen Group
    Boehringer Ingelheim International GmbH
    Eli Lilly & Co.
    F. Hoffmann-La Roche Ltd.
    Novartis AG
    Pfizer Inc.
    Tarveda Therapeutics Inc.
    Teva Pharmaceutical Industries Ltd.

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Somatostatin Analogue Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Somatostatin Analogue Drug, with revenue, gross margin and global market share of Somatostatin Analogue Drug from 2019 to 2024.
Chapter 3, the Somatostatin Analogue Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Somatostatin Analogue Drug market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Somatostatin Analogue Drug.
Chapter 13, to describe Somatostatin Analogue Drug research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Somatostatin Analogue Drug
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Somatostatin Analogue Drug by Type
        1.3.1 Overview: Global Somatostatin Analogue Drug Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global Somatostatin Analogue Drug Consumption Value Market Share by Type in 2023
        1.3.3 Octreotide
        1.3.4 Lanreotide
        1.3.5 Pasireotide
    1.4 Global Somatostatin Analogue Drug Market by Application
        1.4.1 Overview: Global Somatostatin Analogue Drug Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Acromegaly
        1.4.3 Neuroendocrine Tumor (NET)
        1.4.4 Others
    1.5 Global Somatostatin Analogue Drug Market Size & Forecast
    1.6 Global Somatostatin Analogue Drug Market Size and Forecast by Region
        1.6.1 Global Somatostatin Analogue Drug Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global Somatostatin Analogue Drug Market Size by Region, (2019-2030)
        1.6.3 North America Somatostatin Analogue Drug Market Size and Prospect (2019-2030)
        1.6.4 Europe Somatostatin Analogue Drug Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific Somatostatin Analogue Drug Market Size and Prospect (2019-2030)
        1.6.6 South America Somatostatin Analogue Drug Market Size and Prospect (2019-2030)
        1.6.7 Middle East and Africa Somatostatin Analogue Drug Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 Camurus AB
        2.1.1 Camurus AB Details
        2.1.2 Camurus AB Major Business
        2.1.3 Camurus AB Somatostatin Analogue Drug Product and Solutions
        2.1.4 Camurus AB Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Camurus AB Recent Developments and Future Plans
    2.2 Chiasma
        2.2.1 Chiasma Details
        2.2.2 Chiasma Major Business
        2.2.3 Chiasma Somatostatin Analogue Drug Product and Solutions
        2.2.4 Chiasma Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Chiasma Recent Developments and Future Plans
    2.3 Ipsen Group
        2.3.1 Ipsen Group Details
        2.3.2 Ipsen Group Major Business
        2.3.3 Ipsen Group Somatostatin Analogue Drug Product and Solutions
        2.3.4 Ipsen Group Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Ipsen Group Recent Developments and Future Plans
    2.4 Boehringer Ingelheim International GmbH
        2.4.1 Boehringer Ingelheim International GmbH Details
        2.4.2 Boehringer Ingelheim International GmbH Major Business
        2.4.3 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product and Solutions
        2.4.4 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Boehringer Ingelheim International GmbH Recent Developments and Future Plans
    2.5 Eli Lilly & Co.
        2.5.1 Eli Lilly & Co. Details
        2.5.2 Eli Lilly & Co. Major Business
        2.5.3 Eli Lilly & Co. Somatostatin Analogue Drug Product and Solutions
        2.5.4 Eli Lilly & Co. Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Eli Lilly & Co. Recent Developments and Future Plans
    2.6 F. Hoffmann-La Roche Ltd.
        2.6.1 F. Hoffmann-La Roche Ltd. Details
        2.6.2 F. Hoffmann-La Roche Ltd. Major Business
        2.6.3 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product and Solutions
        2.6.4 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
    2.7 Novartis AG
        2.7.1 Novartis AG Details
        2.7.2 Novartis AG Major Business
        2.7.3 Novartis AG Somatostatin Analogue Drug Product and Solutions
        2.7.4 Novartis AG Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Novartis AG Recent Developments and Future Plans
    2.8 Pfizer Inc.
        2.8.1 Pfizer Inc. Details
        2.8.2 Pfizer Inc. Major Business
        2.8.3 Pfizer Inc. Somatostatin Analogue Drug Product and Solutions
        2.8.4 Pfizer Inc. Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Pfizer Inc. Recent Developments and Future Plans
    2.9 Tarveda Therapeutics Inc.
        2.9.1 Tarveda Therapeutics Inc. Details
        2.9.2 Tarveda Therapeutics Inc. Major Business
        2.9.3 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product and Solutions
        2.9.4 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 Tarveda Therapeutics Inc. Recent Developments and Future Plans
    2.10 Teva Pharmaceutical Industries Ltd.
        2.10.1 Teva Pharmaceutical Industries Ltd. Details
        2.10.2 Teva Pharmaceutical Industries Ltd. Major Business
        2.10.3 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product and Solutions
        2.10.4 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2019-2024)
        2.10.5 Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Somatostatin Analogue Drug Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of Somatostatin Analogue Drug by Company Revenue
        3.2.2 Top 3 Somatostatin Analogue Drug Players Market Share in 2023
        3.2.3 Top 6 Somatostatin Analogue Drug Players Market Share in 2023
    3.3 Somatostatin Analogue Drug Market: Overall Company Footprint Analysis
        3.3.1 Somatostatin Analogue Drug Market: Region Footprint
        3.3.2 Somatostatin Analogue Drug Market: Company Product Type Footprint
        3.3.3 Somatostatin Analogue Drug Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Somatostatin Analogue Drug Consumption Value and Market Share by Type (2019-2024)
    4.2 Global Somatostatin Analogue Drug Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global Somatostatin Analogue Drug Consumption Value Market Share by Application (2019-2024)
    5.2 Global Somatostatin Analogue Drug Market Forecast by Application (2025-2030)

6 North America
    6.1 North America Somatostatin Analogue Drug Consumption Value by Type (2019-2030)
    6.2 North America Somatostatin Analogue Drug Consumption Value by Application (2019-2030)
    6.3 North America Somatostatin Analogue Drug Market Size by Country
        6.3.1 North America Somatostatin Analogue Drug Consumption Value by Country (2019-2030)
        6.3.2 United States Somatostatin Analogue Drug Market Size and Forecast (2019-2030)
        6.3.3 Canada Somatostatin Analogue Drug Market Size and Forecast (2019-2030)
        6.3.4 Mexico Somatostatin Analogue Drug Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe Somatostatin Analogue Drug Consumption Value by Type (2019-2030)
    7.2 Europe Somatostatin Analogue Drug Consumption Value by Application (2019-2030)
    7.3 Europe Somatostatin Analogue Drug Market Size by Country
        7.3.1 Europe Somatostatin Analogue Drug Consumption Value by Country (2019-2030)
        7.3.2 Germany Somatostatin Analogue Drug Market Size and Forecast (2019-2030)
        7.3.3 France Somatostatin Analogue Drug Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom Somatostatin Analogue Drug Market Size and Forecast (2019-2030)
        7.3.5 Russia Somatostatin Analogue Drug Market Size and Forecast (2019-2030)
        7.3.6 Italy Somatostatin Analogue Drug Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific Somatostatin Analogue Drug Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific Somatostatin Analogue Drug Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific Somatostatin Analogue Drug Market Size by Region
        8.3.1 Asia-Pacific Somatostatin Analogue Drug Consumption Value by Region (2019-2030)
        8.3.2 China Somatostatin Analogue Drug Market Size and Forecast (2019-2030)
        8.3.3 Japan Somatostatin Analogue Drug Market Size and Forecast (2019-2030)
        8.3.4 South Korea Somatostatin Analogue Drug Market Size and Forecast (2019-2030)
        8.3.5 India Somatostatin Analogue Drug Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia Somatostatin Analogue Drug Market Size and Forecast (2019-2030)
        8.3.7 Australia Somatostatin Analogue Drug Market Size and Forecast (2019-2030)

9 South America
    9.1 South America Somatostatin Analogue Drug Consumption Value by Type (2019-2030)
    9.2 South America Somatostatin Analogue Drug Consumption Value by Application (2019-2030)
    9.3 South America Somatostatin Analogue Drug Market Size by Country
        9.3.1 South America Somatostatin Analogue Drug Consumption Value by Country (2019-2030)
        9.3.2 Brazil Somatostatin Analogue Drug Market Size and Forecast (2019-2030)
        9.3.3 Argentina Somatostatin Analogue Drug Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa Somatostatin Analogue Drug Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa Somatostatin Analogue Drug Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa Somatostatin Analogue Drug Market Size by Country
        10.3.1 Middle East & Africa Somatostatin Analogue Drug Consumption Value by Country (2019-2030)
        10.3.2 Turkey Somatostatin Analogue Drug Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia Somatostatin Analogue Drug Market Size and Forecast (2019-2030)
        10.3.4 UAE Somatostatin Analogue Drug Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 Somatostatin Analogue Drug Market Drivers
    11.2 Somatostatin Analogue Drug Market Restraints
    11.3 Somatostatin Analogue Drug Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Somatostatin Analogue Drug Industry Chain
    12.2 Somatostatin Analogue Drug Upstream Analysis
    12.3 Somatostatin Analogue Drug Midstream Analysis
    12.4 Somatostatin Analogue Drug Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Somatostatin Analogue Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Somatostatin Analogue Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Global Somatostatin Analogue Drug Consumption Value by Region (2019-2024) & (USD Million)
    Table 4. Global Somatostatin Analogue Drug Consumption Value by Region (2025-2030) & (USD Million)
    Table 5. Camurus AB Company Information, Head Office, and Major Competitors
    Table 6. Camurus AB Major Business
    Table 7. Camurus AB Somatostatin Analogue Drug Product and Solutions
    Table 8. Camurus AB Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 9. Camurus AB Recent Developments and Future Plans
    Table 10. Chiasma Company Information, Head Office, and Major Competitors
    Table 11. Chiasma Major Business
    Table 12. Chiasma Somatostatin Analogue Drug Product and Solutions
    Table 13. Chiasma Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 14. Chiasma Recent Developments and Future Plans
    Table 15. Ipsen Group Company Information, Head Office, and Major Competitors
    Table 16. Ipsen Group Major Business
    Table 17. Ipsen Group Somatostatin Analogue Drug Product and Solutions
    Table 18. Ipsen Group Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 19. Ipsen Group Recent Developments and Future Plans
    Table 20. Boehringer Ingelheim International GmbH Company Information, Head Office, and Major Competitors
    Table 21. Boehringer Ingelheim International GmbH Major Business
    Table 22. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product and Solutions
    Table 23. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 24. Boehringer Ingelheim International GmbH Recent Developments and Future Plans
    Table 25. Eli Lilly & Co. Company Information, Head Office, and Major Competitors
    Table 26. Eli Lilly & Co. Major Business
    Table 27. Eli Lilly & Co. Somatostatin Analogue Drug Product and Solutions
    Table 28. Eli Lilly & Co. Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 29. Eli Lilly & Co. Recent Developments and Future Plans
    Table 30. F. Hoffmann-La Roche Ltd. Company Information, Head Office, and Major Competitors
    Table 31. F. Hoffmann-La Roche Ltd. Major Business
    Table 32. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product and Solutions
    Table 33. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 34. F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
    Table 35. Novartis AG Company Information, Head Office, and Major Competitors
    Table 36. Novartis AG Major Business
    Table 37. Novartis AG Somatostatin Analogue Drug Product and Solutions
    Table 38. Novartis AG Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 39. Novartis AG Recent Developments and Future Plans
    Table 40. Pfizer Inc. Company Information, Head Office, and Major Competitors
    Table 41. Pfizer Inc. Major Business
    Table 42. Pfizer Inc. Somatostatin Analogue Drug Product and Solutions
    Table 43. Pfizer Inc. Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 44. Pfizer Inc. Recent Developments and Future Plans
    Table 45. Tarveda Therapeutics Inc. Company Information, Head Office, and Major Competitors
    Table 46. Tarveda Therapeutics Inc. Major Business
    Table 47. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product and Solutions
    Table 48. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 49. Tarveda Therapeutics Inc. Recent Developments and Future Plans
    Table 50. Teva Pharmaceutical Industries Ltd. Company Information, Head Office, and Major Competitors
    Table 51. Teva Pharmaceutical Industries Ltd. Major Business
    Table 52. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product and Solutions
    Table 53. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 54. Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
    Table 55. Global Somatostatin Analogue Drug Revenue (USD Million) by Players (2019-2024)
    Table 56. Global Somatostatin Analogue Drug Revenue Share by Players (2019-2024)
    Table 57. Breakdown of Somatostatin Analogue Drug by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 58. Market Position of Players in Somatostatin Analogue Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
    Table 59. Head Office of Key Somatostatin Analogue Drug Players
    Table 60. Somatostatin Analogue Drug Market: Company Product Type Footprint
    Table 61. Somatostatin Analogue Drug Market: Company Product Application Footprint
    Table 62. Somatostatin Analogue Drug New Market Entrants and Barriers to Market Entry
    Table 63. Somatostatin Analogue Drug Mergers, Acquisition, Agreements, and Collaborations
    Table 64. Global Somatostatin Analogue Drug Consumption Value (USD Million) by Type (2019-2024)
    Table 65. Global Somatostatin Analogue Drug Consumption Value Share by Type (2019-2024)
    Table 66. Global Somatostatin Analogue Drug Consumption Value Forecast by Type (2025-2030)
    Table 67. Global Somatostatin Analogue Drug Consumption Value by Application (2019-2024)
    Table 68. Global Somatostatin Analogue Drug Consumption Value Forecast by Application (2025-2030)
    Table 69. North America Somatostatin Analogue Drug Consumption Value by Type (2019-2024) & (USD Million)
    Table 70. North America Somatostatin Analogue Drug Consumption Value by Type (2025-2030) & (USD Million)
    Table 71. North America Somatostatin Analogue Drug Consumption Value by Application (2019-2024) & (USD Million)
    Table 72. North America Somatostatin Analogue Drug Consumption Value by Application (2025-2030) & (USD Million)
    Table 73. North America Somatostatin Analogue Drug Consumption Value by Country (2019-2024) & (USD Million)
    Table 74. North America Somatostatin Analogue Drug Consumption Value by Country (2025-2030) & (USD Million)
    Table 75. Europe Somatostatin Analogue Drug Consumption Value by Type (2019-2024) & (USD Million)
    Table 76. Europe Somatostatin Analogue Drug Consumption Value by Type (2025-2030) & (USD Million)
    Table 77. Europe Somatostatin Analogue Drug Consumption Value by Application (2019-2024) & (USD Million)
    Table 78. Europe Somatostatin Analogue Drug Consumption Value by Application (2025-2030) & (USD Million)
    Table 79. Europe Somatostatin Analogue Drug Consumption Value by Country (2019-2024) & (USD Million)
    Table 80. Europe Somatostatin Analogue Drug Consumption Value by Country (2025-2030) & (USD Million)
    Table 81. Asia-Pacific Somatostatin Analogue Drug Consumption Value by Type (2019-2024) & (USD Million)
    Table 82. Asia-Pacific Somatostatin Analogue Drug Consumption Value by Type (2025-2030) & (USD Million)
    Table 83. Asia-Pacific Somatostatin Analogue Drug Consumption Value by Application (2019-2024) & (USD Million)
    Table 84. Asia-Pacific Somatostatin Analogue Drug Consumption Value by Application (2025-2030) & (USD Million)
    Table 85. Asia-Pacific Somatostatin Analogue Drug Consumption Value by Region (2019-2024) & (USD Million)
    Table 86. Asia-Pacific Somatostatin Analogue Drug Consumption Value by Region (2025-2030) & (USD Million)
    Table 87. South America Somatostatin Analogue Drug Consumption Value by Type (2019-2024) & (USD Million)
    Table 88. South America Somatostatin Analogue Drug Consumption Value by Type (2025-2030) & (USD Million)
    Table 89. South America Somatostatin Analogue Drug Consumption Value by Application (2019-2024) & (USD Million)
    Table 90. South America Somatostatin Analogue Drug Consumption Value by Application (2025-2030) & (USD Million)
    Table 91. South America Somatostatin Analogue Drug Consumption Value by Country (2019-2024) & (USD Million)
    Table 92. South America Somatostatin Analogue Drug Consumption Value by Country (2025-2030) & (USD Million)
    Table 93. Middle East & Africa Somatostatin Analogue Drug Consumption Value by Type (2019-2024) & (USD Million)
    Table 94. Middle East & Africa Somatostatin Analogue Drug Consumption Value by Type (2025-2030) & (USD Million)
    Table 95. Middle East & Africa Somatostatin Analogue Drug Consumption Value by Application (2019-2024) & (USD Million)
    Table 96. Middle East & Africa Somatostatin Analogue Drug Consumption Value by Application (2025-2030) & (USD Million)
    Table 97. Middle East & Africa Somatostatin Analogue Drug Consumption Value by Country (2019-2024) & (USD Million)
    Table 98. Middle East & Africa Somatostatin Analogue Drug Consumption Value by Country (2025-2030) & (USD Million)
    Table 99. Somatostatin Analogue Drug Raw Material
    Table 100. Key Suppliers of Somatostatin Analogue Drug Raw Materials
List of Figures
    Figure 1. Somatostatin Analogue Drug Picture
    Figure 2. Global Somatostatin Analogue Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Somatostatin Analogue Drug Consumption Value Market Share by Type in 2023
    Figure 4. Octreotide
    Figure 5. Lanreotide
    Figure 6. Pasireotide
    Figure 7. Global Somatostatin Analogue Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 8. Somatostatin Analogue Drug Consumption Value Market Share by Application in 2023
    Figure 9. Acromegaly Picture
    Figure 10. Neuroendocrine Tumor (NET) Picture
    Figure 11. Others Picture
    Figure 12. Global Somatostatin Analogue Drug Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 13. Global Somatostatin Analogue Drug Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 14. Global Market Somatostatin Analogue Drug Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
    Figure 15. Global Somatostatin Analogue Drug Consumption Value Market Share by Region (2019-2030)
    Figure 16. Global Somatostatin Analogue Drug Consumption Value Market Share by Region in 2023
    Figure 17. North America Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 18. Europe Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 19. Asia-Pacific Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 20. South America Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 21. Middle East and Africa Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 22. Global Somatostatin Analogue Drug Revenue Share by Players in 2023
    Figure 23. Somatostatin Analogue Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
    Figure 24. Global Top 3 Players Somatostatin Analogue Drug Market Share in 2023
    Figure 25. Global Top 6 Players Somatostatin Analogue Drug Market Share in 2023
    Figure 26. Global Somatostatin Analogue Drug Consumption Value Share by Type (2019-2024)
    Figure 27. Global Somatostatin Analogue Drug Market Share Forecast by Type (2025-2030)
    Figure 28. Global Somatostatin Analogue Drug Consumption Value Share by Application (2019-2024)
    Figure 29. Global Somatostatin Analogue Drug Market Share Forecast by Application (2025-2030)
    Figure 30. North America Somatostatin Analogue Drug Consumption Value Market Share by Type (2019-2030)
    Figure 31. North America Somatostatin Analogue Drug Consumption Value Market Share by Application (2019-2030)
    Figure 32. North America Somatostatin Analogue Drug Consumption Value Market Share by Country (2019-2030)
    Figure 33. United States Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 34. Canada Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 35. Mexico Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 36. Europe Somatostatin Analogue Drug Consumption Value Market Share by Type (2019-2030)
    Figure 37. Europe Somatostatin Analogue Drug Consumption Value Market Share by Application (2019-2030)
    Figure 38. Europe Somatostatin Analogue Drug Consumption Value Market Share by Country (2019-2030)
    Figure 39. Germany Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 40. France Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 41. United Kingdom Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 42. Russia Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 43. Italy Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 44. Asia-Pacific Somatostatin Analogue Drug Consumption Value Market Share by Type (2019-2030)
    Figure 45. Asia-Pacific Somatostatin Analogue Drug Consumption Value Market Share by Application (2019-2030)
    Figure 46. Asia-Pacific Somatostatin Analogue Drug Consumption Value Market Share by Region (2019-2030)
    Figure 47. China Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 48. Japan Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 49. South Korea Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 50. India Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 51. Southeast Asia Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 52. Australia Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 53. South America Somatostatin Analogue Drug Consumption Value Market Share by Type (2019-2030)
    Figure 54. South America Somatostatin Analogue Drug Consumption Value Market Share by Application (2019-2030)
    Figure 55. South America Somatostatin Analogue Drug Consumption Value Market Share by Country (2019-2030)
    Figure 56. Brazil Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 57. Argentina Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 58. Middle East and Africa Somatostatin Analogue Drug Consumption Value Market Share by Type (2019-2030)
    Figure 59. Middle East and Africa Somatostatin Analogue Drug Consumption Value Market Share by Application (2019-2030)
    Figure 60. Middle East and Africa Somatostatin Analogue Drug Consumption Value Market Share by Country (2019-2030)
    Figure 61. Turkey Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 62. Saudi Arabia Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 63. UAE Somatostatin Analogue Drug Consumption Value (2019-2030) & (USD Million)
    Figure 64. Somatostatin Analogue Drug Market Drivers
    Figure 65. Somatostatin Analogue Drug Market Restraints
    Figure 66. Somatostatin Analogue Drug Market Trends
    Figure 67. Porters Five Forces Analysis
    Figure 68. Manufacturing Cost Structure Analysis of Somatostatin Analogue Drug in 2023
    Figure 69. Manufacturing Process Analysis of Somatostatin Analogue Drug
    Figure 70. Somatostatin Analogue Drug Industrial Chain
    Figure 71. Methodology
    Figure 72. Research Process and Data Source

Companies Mentioned

Camurus AB
Chiasma
Ipsen Group
Boehringer Ingelheim International GmbH
Eli Lilly & Co.
F. Hoffmann-La Roche Ltd.
Novartis AG
Pfizer Inc.
Tarveda Therapeutics Inc.
Teva Pharmaceutical Industries Ltd.